Pulmonary Embolism Clinical Trial
Official title:
Eighteen Months of Oral Anticoagulant Therapy Versus Placebo After 6 Six Months of Anticoagulation for a First Episode of Idiopathic Pulmonary Embolism: a Multicentre Double-blind Randomized Controlled Trial. "PADIS-PE" Study.
Rational: After 3 or 6 months of oral anticoagulation for an episode of acute venous
thromboembolism (VTE), the risk of recurrent VTE is high (10 to 15% per year) in comparison
with a low risk of recurrence if VTE was provoked by a major transient risk factor such as
recent surgery (3% per year) independently of the initial presentation (deep vein thrombosis
or pulmonary embolism). After a first episode of idiopathic VTE, 3 months of anticoagulation
is associated with a very high risk of recurrence (27% per year); however, the benefit-risk
of extended duration of anticoagulation (1 to 2 years) remains uncertain, mainly in relation
with an increased risk of anticoagulant related bleeding. Therefore, the last ACCP
conference group recommended 6 months of oral anticoagulant therapy after a first episode of
idiopathic VTE. However, this recommendation is likely to be inadequate for at least two
main reasons: (1) no studies compared 2 years to 6 months of anticoagulation after
idiopathic VTE; and (2), if the frequency of recurrent VTE is similar after deep vein
thrombosis and pulmonary embolism, however, the case fatality rate of recurrent VTE is
higher after pulmonary embolism (12%) than after deep vein thrombosis (5%).
Objective : the main objective is to demonstrate that, after 6 months of oral
anticoagulation for a first episode of idiopathic pulmonary embolism, 18 months of warfarin
therapy is associated with a lower cumulative risk of recurrent VTE and major bleeding in
comparison with that on 18 months of placebo. The secondary objectives are: (1) to determine
the risk of recurrent VTE after 6 months of warfarin therapy and the presence or the absence
of residual lung scan perfusion defect and the persistence or not of elevated D-dimer test;
and (2), to determine the impact of extended duration of anticoagulation on the risk of VTE
after stopping anticoagulant therapy on a follow-up of 2 years.
Method : French multicenter double blind randomized controlled trial. Inclusion and
exclusion criteria and pulmonary diagnostic criteria have been defined. After completing 6
months of oral anticoagulation, a lung scan and D-dimer testing are performed; the
investigators and the patients will be unaware of the results of these tests. Then, patients
are randomized to receive 18 months of warfarin therapy or 18 months of placebo (the dose of
placebo will be adapted according to false computer generated INR). The investigators, the
radiologists and the patients are blinded of the treatment allocation. The project will be
submitted to national ethical committee and written consent will be obtained from all
included patients.
Required number of patients: the expected cumulative frequency of recurrent VTE and major
bleeding over 18 months is 4.5% while on warfarin therapy and 16% while on placebo. For a α
risk of 5% (to falsely conclude to a true difference) and a β risk of 10% (to falsely
conclude to an absence of difference), 178 patients per group should be included. As 5% of
patients are expected to be loss, a total of 374 patients is required.
Feasibility: about 50 patients per year are hospitalized in our department of medicine in
Brest for an acute episode of idiopathic pulmonary embolism. Four additional centers will
participate to the study and have a similar recruitment: HEGP (Pr Meyer, Dr Sanchez), CHU
Antoine Béclère (Dr Parent, Pr Simmoneau), CHU Saint Etienne (Pr Mismetti, Pr Décousus), CHU
Grenoble (Pr Pison, Pr Carpentier). The study will be coordinated by the Clinical Center of
Investigation of Brest Hospital; "true" and "false" INR will be generated by the clinic of
anticoagulant of "Ile de France" (Dr Cambus).
Clinical implications: the first consequence of the study is to demonstrate that 6 months of
warfarin therapy is inadequate and should be continued for at least 18 additional months
after a first episode of idiopathic pulmonary embolism. This study has also the potential to
confirm or not the contribution of lung scan and D-dimer testing to appreciate the risk of
recurrent VTE after stopping anticoagulant therapy. Lastly, the medical economical impact of
such therapeutic management will be evaluated.
Rational: After 3 or 6 months of oral anticoagulation for an episode of acute venous
thromboembolism (VTE), the risk of recurrent VTE is high (10 to 15% per year) in comparison
with a low risk of recurrence if VTE was provoked by a major transient risk factor such as
recent surgery (3% per year) independently of the initial presentation (deep vein thrombosis
or pulmonary embolism). After a first episode of idiopathic VTE, 3 months of anticoagulation
is associated with a very high risk of recurrence (27% per year); however, the benefit-risk
of extended duration of anticoagulation (1 to 2 years) remains uncertain, mainly in relation
with an increased risk of anticoagulant related bleeding. Therefore, the last ACCP
conference group recommended 6 months of oral anticoagulant therapy after a first episode of
idiopathic VTE. However, this recommendation is likely to be inadequate for at least two
main reasons: (1) no studies compared 2 years to 6 months of anticoagulation after
idiopathic VTE; and (2), if the frequency of recurrent VTE is similar after deep vein
thrombosis and pulmonary embolism, however, the case fatality rate of recurrent VTE is
higher after pulmonary embolism (12%) than after deep vein thrombosis (5%).
Objective : the main objective is to demonstrate that, after 6 months of oral
anticoagulation for a first episode of idiopathic pulmonary embolism, 18 months of warfarin
therapy is associated with a lower cumulative risk of recurrent VTE and major bleeding in
comparison with that on 18 months of placebo. The secondary objectives are: (1) to determine
the risk of recurrent VTE after 6 months of warfarin therapy and the presence or the absence
of residual lung scan perfusion defect and the persistence or not of elevated D-dimer test;
and (2), to determine the impact of extended duration of anticoagulation on the risk of VTE
after stopping anticoagulant therapy on a follow-up of 2 years.
Method : French multicenter double blind randomized controlled trial. Inclusion and
exclusion criteria and pulmonary diagnostic criteria have been defined. After completing 6
months of oral anticoagulation, a lung scan and D-dimer testing are performed; the
investigators and the patients will be unaware of the results of these tests. Then, patients
are randomized to receive 18 months of warfarin therapy or 18 months of placebo (the dose of
placebo will be adapted according to false computer generated INR). The investigators, the
radiologists and the patients are blinded of the treatment allocation. The project will be
submitted to national ethical committee and written consent will be obtained from all
included patients.
Required number of patients: the expected cumulative frequency of recurrent VTE and major
bleeding over 18 months is 4.5% while on warfarin therapy and 16% while on placebo. For a α
risk of 5% (to falsely conclude to a true difference) and a β risk of 10% (to falsely
conclude to an absence of difference), 178 patients per group should be included. As 5% of
patients are expected to be loss, a total of 374 patients is required.
Feasibility: about 50 patients per year are hospitalized in our department of medicine in
Brest for an acute episode of idiopathic pulmonary embolism. Four additional centers will
participate to the study and have a similar recruitment: HEGP (Pr Meyer, Dr Sanchez), CHU
Antoine Béclère (Dr Parent, Pr Simmoneau), CHU Saint Etienne (Pr Mismetti, Pr Décousus), CHU
Grenoble (Pr Pison, Pr Carpentier). The study will be coordinated by the Clinical Center of
Investigation of Brest Hospital; "true" and "false" INR will be generated by the clinic of
anticoagulant of "Ile de France" (Dr Cambus).
Clinical implications: the first consequence of the study is to demonstrate that 6 months of
warfarin therapy is inadequate and should be continued for at least 18 additional months
after a first episode of idiopathic pulmonary embolism. This study has also the potential to
confirm or not the contribution of lung scan and D-dimer testing to appreciate the risk of
recurrent VTE after stopping anticoagulant therapy. Lastly, the medical economical impact of
such therapeutic management will be evaluated.
;
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05050617 -
Point-of-Care Ultrasound in Predicting Adverse Outcomes in Emergency Department Patients With Acute Pulmonary Embolism
|
||
Terminated |
NCT04558125 -
Low-Dose Tenecteplase in Covid-19 Diagnosed With Pulmonary Embolism
|
Phase 4 | |
Not yet recruiting |
NCT06017271 -
Predictive Value of Epicardial Adipose Tissue for Pulmonary Embolism and Death in Patients With Lung Cancer
|
||
Completed |
NCT03915925 -
Short-term Clinical Deterioration After Acute Pulmonary Embolism
|
||
Completed |
NCT02502396 -
Rivaroxaban Utilization for Treatment and Prevention of Thromboembolism in Cancer Patients: Experience at a Comprehensive Cancer Center
|
||
Recruiting |
NCT05171075 -
A Study Comparing Abelacimab to Dalteparin in the Treatment of Gastrointestinal/Genitourinary Cancer and Associated VTE
|
Phase 3 | |
Completed |
NCT04454554 -
Prevalence of Pulmonary Embolism in Patients With Dyspnea on Exertion (PEDIS)
|
||
Completed |
NCT03173066 -
Ferumoxytol as a Contrast Agent for Pulmonary Magnetic Resonance Angiography
|
Phase 1 | |
Terminated |
NCT03002467 -
Impact Analysis of Prognostic Stratification for Pulmonary Embolism
|
N/A | |
Completed |
NCT02611115 -
Optimizing Protocols for the Individual Patient in CT Pulmonary Angiography.
|
N/A | |
Completed |
NCT02334007 -
Extended Low-Molecular Weight Heparin VTE Prophylaxis in Thoracic Surgery
|
Phase 1/Phase 2 | |
Completed |
NCT01975090 -
The SENTRY Clinical Study
|
N/A | |
Not yet recruiting |
NCT01357941 -
Need for Antepartum Thromboprophylaxis in Pregnant Women With One Prior Episode of Venous Thromboembolism (VTE)
|
N/A | |
Completed |
NCT01326507 -
Prognostic Value of Heart-type Fatty Acid-Binding Protein (h-FABP) in Acute Pulmonary Embolism
|
N/A | |
Completed |
NCT00773448 -
Screening for Occult Malignancy in Patients With Idiopathic Venous Thromboembolism
|
N/A | |
Completed |
NCT00780767 -
Angiojet Rheolytic Thrombectomy in Case of Massive Pulmonary Embolism
|
Phase 2 | |
Completed |
NCT02476526 -
Safety of Low Dose IV Contrast CT Scanning in Chronic Kidney Disease
|
Phase 4 | |
Completed |
NCT00771303 -
Ruling Out Pulmonary Embolism During Pregnancy:a Multicenter Outcome Study
|
||
Completed |
NCT00720915 -
D-dimer to Select Patients With First Unprovoked Venous Thromboembolism Who Can Have Anticoagulants Stopped at 3 Months
|
N/A | |
Completed |
NCT00244725 -
Odiparcil For The Prevention Of Venous Thromboembolism
|
Phase 2 |